Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.

American journal of clinical oncology - 1 Aug 2018

Gleeson Elizabeth M, Feldman Rebecca, Mapow Beth L, Mackovick Lynn T, Ward Kristine M, Morano William F, Rubin Rene R, Bowne Wilbur B

Abstract excerpt

OBJECTIVES: Pseudomyxoma peritonei (PMP) is a rare malignancy originating from the appendix, characterized by disseminated mucinous tumor implants on peritoneal surfaces. We examined the role of multiplatform molecular profiling to study biomarker-guided treatment strategies for this rare malignancy. METHODS: A total of 54 patients with appendix-derived PMP were included in the study. Tests included one or more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Gene Expression Profiling

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Patient Selection

Share to Peritoneal Neoplasms

Source

Identifiers

PMID: 28263231
DOI: 10.1097/COC.0000000000000376

Genes

KRAS
GNAS
APC
ATM
BRAF
ERCC1
MLH1
PGP
RRM1
SMAD4
TLE3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.PMID 28263231Read ↗

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.Semantic proximity Read ↗

Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.Semantic proximity Read ↗

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.Semantic proximity Read ↗

Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.Semantic proximity Read ↗

Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.Semantic proximity Read ↗

Whole-Exome Sequencing Identifies Mutation Profile and Mutation Signature-Based Clustering Associated with Prognosis in Appendiceal Pseudomyxoma Peritonei.Semantic proximity Read ↗

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.Semantic proximity Read ↗

Toward the molecular dissection of peritoneal pseudomyxoma.Semantic proximity Read ↗

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.Semantic proximity Read ↗

Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell linesSemantic proximity Read ↗

Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.Semantic proximity Read ↗

Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.